Timecode RENAL & DIABETES

Part 1 - 29 MB RENAL 1

- 0 Introduction
- 0.29 Renal
- 0.32 History symptoms
- 4.17 Uraemia
- 7.52 Causes of renal impairment
- 8.15 Drug history
- 9.05 Rest of history
- 9.52 Examination
 - 10 ENDS

Part 2 - 29 MB RENAL 2

- 0 Examination continued
- 2.32 Hands
- 4.23 Blood pressure
- 5.11 Capillary blood glucose
- 5.42 Temperature
- 5.53 Face
- 7.24 Neck
- 7.54 Respiratory system
- 8.03 Heart
- 8.45 Abdomen characteristics of a renal mass as opposed to liver or spleen
 - 10 ENDS

Part 3 - 29 MB RENAL 3

- 0 Abdomen characteristics of a renal mass as opposed to liver or spleen continued
- 2.03 Peripheral circulation
- 2.43 Ensure patient is comfortable
- 2.52 Presentation of findings
- 3.13 Investigations
- 3.16 Bloods
- 5.03 Microbiology
- 8.25 Organisms that cause urinary tract infections
- 9.29 Treatment antibiotics
- 10.02 ENDS

Part 4 - 29 MB RENAL 4

- 0 Treatment antibiotics continued
- 3.33 Red cell casts tubular damage
- 4.21 Proteinuria
- 5.37 Urinary protein: creatinine ratio
- 8.49 Other investigations
- 9.22 Radiology
- 9.59 ENDS

Part 5 - 29 MB RENAL 5

- 0 Radiology
- 1.17 Causes
- 1.55 Pre-renal
- 2.41 Obstructive
- 5.01 Treatment
- 5.31 Renal
- 6.4 Common causes of glomerulonephritis
- 9.35 Acute versus chronic renal failure

	Definition of organ failure ENDS
Part 6 - 29 MB	RENAL 6 Functions of the kidney

3.41 Renal failure5.54 Acute versus chronic renal failure

8.4 Tests to do when patient in renal failure

8.58 Pre-renal versus renal versus obstructive

9.53 ENDS

Part 7 - 30 MB RENAL 7

0 Pre-renal versus renal versus obstructive

0.11 Urea:creatinine ratio

1.29 Ultrasound

1.55 Urinary sodium and urinary osmolality

3.09 Top five causes of acute renal failure

5.36 Top five causes of chronic renal failure

6.13 Check drug chart - drugs cause everything

6.47 Management of acute renal failure

10 ENDS

Part 8 - 18 MB RENAL 8

0 Management of acute renal failure continued

5.15 Reasons for low urine output on surgical wards

6.09 ENDS

Part 9 - 30 MB DIABETES 1

0 Introduction

0.45 Definitions

3.3 Types

4.52 Type 1 Diabetes Mellitus

5.43 Presentation - symptoms

6.38 Type 2 Diabetes Mellitus

7.05 Presentation - symptoms

8.11 Examination of the well diabetic patient - annual review

9.39 Macrovascular complications

10.01 ENDS

Part 10 - 29 MB DIABETES 2

0 Macrovascular complications continued

0.21 Microvascular complications

1.26 Diabetic retinopathy

3.43 Eye disease

4.43 Feet

5.1 Neurology

5.29 Causes of peripheral sensory neuropathy

6.29 Neurological complications of diabetes

7.48 Summary of all complications of diabetes

8.45 Diabetic coma

9.01 Hypoglycaemia

10.02 ENDS

Part 11 - 28 MB DIABETES 3

0 Hypoglycaemia continued

1.16 Underlying cause

1.58 Management

- 4 Hyperglycaemia
- 4.06 Diabetic ketoacidosis
- 4.16 Presentation
- 5.07 Confirm diagnosis investigations
- 6.53 Corroborative history
- 7.27 Examination
- 8.08 Initial management
- 8.53 Investigations
 - 10 ENDS

Part 12 - 28 MB DIABETES 4

- 0 Investigations
- 0.37 Senior review
- 0.5 Treatment
- 1.33 Fluids
- 6.47 Potassium
- 8.03 Low molecular weight heparin
- 8.37 Treat underlying cause
- 8.59 NG tube
- 9.34 Insulin sliding scale
 - 10 ENDS

Part 13 - 28 MB DIABETES 5

- 0 Insulin sliding scale continued
- 0.15 Blood glucose and units of insulin to give per hour
- 4.24 Hyperosmolar non-ketotic coma
- 4.45 Causes
- 5.36 Initial investigations and management
- 6.36 Insulin sliding scale
- 8.09 Fluids
- 9.33 Low molecular weight heparin
- 10.02 ENDS

Part 14 - 28 MB DIABETES 6

- 0 Treat underlying cause
- 0.15 Management insulin regimes once eating and drinking in hospital Four times-daily regime
- 6.45 Twice-daily regime
- 8.51 HBA1c measure control over past three months
- 9.53 Chronic disease management
- 10.01 ENDS

Part 15 - 36 MB DIABETES 7

- 0 Five questions to ask chronic disease managemen
- Four-step generic management of any chronic disease Education, Risk Factors,
- 0.19 Multidisciplinary Team, Drugs
- 0.47 Insulin
- 1.01 Oral hypoglycaemics
- 1.21 Biguanides metformin
- 5.08 Sulphonylureas compared with biguanides
- 5.47 Sulphonylureas and half-life
- 7.07 Glitazones
- 7.47 Repaglinide group
- 8.37 Acarbose
- 9.08 Gliptins and GLP-1 mimetics
- 12.16 ENDS